Introduction
A two hit model of leukaemogenesis combining an activating lesion of tyrosine kinase pathways to an event blocking myeloid differentiation has been suggested in the physiopathology of acute myeloid leukaemia (AML). 1, 2 In agreement with this hypothesis, the association between AML1 mutation and FLT3 gene alterations has been described in M0 FAB subtype AML. 3, 4 To further document this model in M0 AML, we screened a cohort of 45 patients with M0 AML for mutations of genes implicated in myeloid differentiation (including AML1 and Pu1) and genes contributing to cell proliferation via alterations of tyrosine kinase (FLT3, N-RAS, K-RAS, c-KIT) or tyrosine phosphatase pathway (PTPN11).
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Materials and methods
Bone marrow and peripheral blood samples were obtained before therapy in 45 patients with M0 AML, after informed consent. Diagnosis of M0 AML was based on cytology, cytochemistry and immunophenotyping criteria: analysis of bone marrow and peripheral blood smears stained by MayGrü nwald-Giemsa, myeloperoxidase, naphtol AS-D-acetate esterases with and without fluoride inhibition, or naphthyl acetate butyrate esterase cytochemical reactions were performed. 3 Immunophenotyping was performed by flow cytometry. Diagnostic criteria of M0 AML were as follows: (i) o3% myeloperoxydase positive blasts, (ii) expression of at least one of the following myeloid markers: CD13, CD33 or MPO, (iii) no expression of lymphoid markers except CD4 or CD7 (EGIL criteria).
11 Molecular studies were made according to previously published methods for AML1, Pu1, FLT3, PTPN11, Ras and c-kit mutations. 6, 7, 9, 10 Treatment was based on age and performance status. Most patients received intensive Ara-C and anthracycline chemotherapy according to French multicenter trials (LAM90, BGMT, EORTC and GOELAMS cooperative groups).
Results
They are summarized in Table 1 .
Clinical, haematological and cytogenetic findings
Median age of the 45 patients was 61 years (range 15-88 years) and M/F 1.6 (17 female and 28 male patients). Three patients were younger than 20 years. Median WBC was 37.5 G/l, median peripheral blast percentage 83% and median marrow blast percentage 88%.
Karyotype was available in 33 of the 45 patients (Table 1) . Eighteen (54%) of them had clonal abnormalities of whom eight (44%) had complex karyotype (i.e. three or more abnormalities). Unbalanced rearrangements affecting chromosomes 5 or 7 were found in seven patients. Abnormalities of chromosome 3 were found in four cases, with a breakpoint located in 3q21 or q26 in two cases. Abnormalities of 11q23 band were seen in two cases and loss of chromosome 21 was found in two patients.
Molecular findings
No mutation of the Pu1 gene was observed, whereas mutation in the Runt domain of AML1 gene was observed in 12 of 45 patients (25%). No Asp 816 point mutation or insertion-deletion in exon 8 of the c-kit gene was found. Three Asp835Val point mutations (7%) and 11 internal tandem duplications (22%) were seen in the FLT3 gene. Two N-RAS mutations were seen, including a Gly12val point mutation in exon1 in one patient and a Gln61His point mutation in exon 2 in another patient. No K-RAS gene mutation was seen. Mutational analysis of exon 3 and exon 13 of the PTPN11 gene was made and only one patient had a point mutation (E76G). Six of the 12 patients (50%) with AML1 gene mutation also had alterations of genes implicated in cell proliferation pathways (four patients with ITD FLT3 duplications, one with FLT3 point mutation and one N-ras point mutation) as compared to 10 of the 33 patients (30%) without detectable AML1 mutation (seven patients with FLT3-ITD, one with FLT3-ITD combined to FLT3 mutation, one with RAS mutation and one with PTPN11 mutation) (P ¼ 0.32, Fisher exact test). There was also no significant correlation between AML1 mutation and FLT3 mutation (P ¼ 0.28).
Interestingly, cases without AML1 mutation had a significantly higher rate of cytogenetic abnormalities than cases with AML1 mutation (17/26 vs 1/7, P ¼ 0.03, Fisher exact test). More generally, cases without any detectable gene mutations tend to have a higher frequency of cytogenetic abnormalities: among the 24 patients without molecular abnormalities, karyotype, available in 17 cases, was normal in five cases and abnormal in 12 cases (72%) including six complex karyotypes and among the 21 patients with molecular abnormalities, karyotype, available in 16 cases, was normal in 10 cases (67%) and abnormal in six cases ( þ 8, À7 and inv (3)(q21q26), isochr (7) and two complex karyotypes), (P ¼ 0.08, Fisher exact test).
There was no significant difference of incidence of class I genes mutation between patients with abnormal cytogenetic (6/18, 33% of patients vs 8/15, 53% patients) and patients with normal karyotype (P ¼ 0.3, Fisher exact test).
Discussion
M0 AML is a subtype of AML characterized by high white cells count, high incidence of cytogenetic abnormalities, frequent AML1 gene mutation and poor prognosis. 12, 13 To better document the respective role of AML1 mutations and other molecular or cytogenetic events in the development of M0 AML, we looked for mutations of other genes critical in myeloid differentiation or in cell proliferation pathways in a large series of M0 AML. We confirmed the high incidence of AML1 mutation. Another gene implicated in early stages of myeloid differentiation, PU-1, was analysed but abnormalities were not found. The incidence of FLT3 ITD alterations (22%) and D835 mutation (7%) was similar to that reported in AML in general and more specifically in M0. [14] [15] [16] This is in contrast with other core binding factor (CBF) AML subtypes with the alteration of AML1 or CBFb genes through balanced translocations (t(8;21) or inv(16)). [17] [18] [19] These patients have very low frequency of FLT3 ITD but often have c-Kit or RAS mutation. 14, 20, 21 The incidence of c-Kit alteration (2%) or Ras family genes mutation (4%) and PTPN11 mutation (2%) was very low in the present series.
We also found no significant correlation between AML1 mutations and alterations in genes involved in cell proliferation pathways, more precisely, with FLT3 alteration a result in contradiction with a previous study. 4 Discrepancies could be due to the fact that both works included small numbers of patients or because of differences between the characteristics of the patients with AML1 mutations (in our series, all patients had at least two AML1 alterations, generally mutation on one allele and deletion of the other (10 of the 12 patients); this obviously great percentage of biallelic alterations induce complete inactivation of AML1 function, which is probably sufficient to trigger leukaemogenesis). Such results suggest that the cooperative model in myeloid leukaemogenesis implicate, on the one hand, inactivation of myeloid differentiation, and on the other hand, lesion in cell proliferation pathways such as tyrosine kinase constitutive activation cannot easily explain leukaemogenesis in M0 AML. In M0 AML, an event blocking differentiation was clearly identified in only 25% of the cases where AML1 inactivation was found. We did not find in our patients mutation of Pu1, another early myeloid differentiation master gene PU1. Thus, the cell differentiation block in most M0 AML cases must result from other genetic abnormalities. We also found that cases with no AML1 mutation, and more generally, cases without detectable mutation had a significant higher rate of cytogenetic abnormalities than mutated cases, suggesting that these two types of abnormalities may often be mutually exclusive. These results suggest that there could be at least two different groups in M0 AML possibly with different mechanisms of leukaemogenesis: one group of patients generally associated with normal cytogenetics and mutational events involving AML1 genes and/or other mutations involving FLT3 gene; the second group with abnormal cytogenetics often complex without AML1 mutation. In the second group, genetic mechanisms leading to AML remain unknown.
The first group may respond to a two hit model of leukaemogenesis where AML1 mutation could be the initial event and a class I gene alteration the critical event inducing progression to leukaemia. 8 The recent report that, in MDS and AML studied sequentially, AML1 mutations were found early whereas RAS mutations only occurred in the latest samples may strengthen this multistep hypothesis in leukaemogenesis. 22 The propensity of FPD (Familial Platelet Disease) patients to develop acute leukaemia and the higher frequency of FLT3 mutation at relapse in AML as compared to diagnosis also support this hypothesis. 23 Those perturbations largely results from deregulation of genes involved in cell maintenance and DNA repair. 24 Previous studies in AML have shown that, in pathways deregulated by AML-specific fusion proteins (including AML1-ETO, PML-RARa, or PLZF-RARa), inactivation of DNA repair function leads to an increase in the rate of secondary mutations, which were the direct consequence of the fusion protein.
